UTHR · Company research
United Therapeutics Corp (UTHR): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
34records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. - Stock Titan | A Houston site is built to make pig kidneys and hearts for United Therapeutics’ organ program. Stock Titan | View source ↗ | Stock Titan | Oct 20, 2026 | neutral | 0 | 0.6 |
| UTHR Stock Quote Price and Forecast - CNN | UTHR Stock Quote Price and Forecast CNN | View source ↗ | CNN | Oct 20, 2026 | neutral | 0 | 0.6 |
| After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan | After exercising options at $117.76, CEO trust sells 9,500 United Therapeutics (UTHR) shares. Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years - Benzinga | Here’s How Much You Would Have Made Owning United Therapeutics Stock In The Last 5 Years Benzinga | View source ↗ | Benzinga | Oct 19, 2026 | neutral | 0 | 0.6 |
| Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. - Stock Titan | Up to 800,000 people have high blood pressure in the lungs linked to chronic lung disease. An inhaler trial can proceed. Stock Titan | View source ↗ | Stock Titan | Oct 19, 2026 | neutral | 0 | 0.6 |
| An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. - Stock Titan | An 8,300-share planned sale follows an option exercise by United Therapeutics (UTHR) counsel. Stock Titan | View source ↗ | Stock Titan | Oct 16, 2026 | neutral | 0 | 0.6 |
| Is United Therapeutics (UTHR) Undervalued After Its Legal Settlement? - Yahoo Finance | Is United Therapeutics (UTHR) Undervalued After Its Legal Settlement? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement - Yahoo Finance | United Therapeutics (UTHR) Stock May Be Undervalued Following The Litigation Settlement Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. - Stock Titan | A CEO trust exercises options at $117.76 and sells 9,500 United Therapeutics (UTHR) shares. Stock Titan | View source ↗ | Stock Titan | Oct 14, 2026 | neutral | 0 | 0.6 |
| LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label | Liquidia Corporation has reached a global settlement with United Therapeutics, resolving all six pending legal disputes and ensuring continued access to Yutrepia for PAH patients. However, the company must pay $380.7 million in settlement obligations across 2026-2027, and the removal of the PH-ILD indication from Yutrepia's label narrows its approved use. The company reported preliminary Q3 2026 Yutrepia sales of $222.7 million and plans to advance pipeline candidate L606. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| SGIOY or UTHR: Which Is the Better Value Stock Right Now? | In a comparison of two medical-drugs stocks, Shionogi & Co., Ltd. (SGIOY) emerges as the superior value option compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 10.68 versus UTHR's 20.59, and a more favorable P/B ratio of 1.34 compared to UTHR's 3.64. UTHR carries a Zacks Rank #3 (Hold) with a Value grade of C. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| SGIOY or UTHR: Which Is the Better Value Stock Right Now? - Yahoo Finance | SGIOY or UTHR: Which Is the Better Value Stock Right Now? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| SGIOY or UTHR: Which Is the Better Value Stock Right Now? | In a comparison of two medical-drugs stocks, Shionogi & Co., Ltd. (SGIOY) emerges as the superior value option compared to United Therapeutics (UTHR). SGIOY holds a Zacks Rank #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 10.68 versus UTHR's 20.59, and a more favorable P/B ratio of 1.34 compared to UTHR's 3.64. UTHR carries a Zacks Rank #3 (Hold) with a Value grade of C. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.5 | 1 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains the Zacks Earnings ESP (Expected Surprise Prediction) tool, which identifies potential earnings surprises by comparing the Most Accurate Estimate to the Zacks Consensus Estimate. Historical data shows that combining a positive ESP with a Zacks Rank #3 or better has resulted in positive earnings surprises 70% of the time, with average annual returns of 28.3%. The article highlights Halozyme Therapeutics and United Therapeutics as examples of stocks with positive ESP figures ahead of their earnings releases. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| United Therapeutics Corporation (UTHR) stock price, news, quote and history - Yahoo Finance UK | United Therapeutics Corporation (UTHR) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 14, 2026 | neutral | 0 | 0.6 |
| The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. - Stock Titan | The CEO’s family trust sold 9,500 United Therapeutics (UTHR) shares under a pre-arranged trading plan. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. - Stock Titan | After exercising options at $117.76, the CEO's trust sold 9,500 United Therapeutics (UTHR) shares. Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring - Stock Titan | An inhaled drug still being tested reduced the risk of multiple worsening events for people with lung scarring Stock Titan | View source ↗ | Stock Titan | Oct 13, 2026 | neutral | 0 | 0.6 |
| MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits | MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ Stocktwits | View source ↗ | Stocktwits | Oct 13, 2026 | neutral | 0 | 0.6 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains how the Zacks Earnings ESP (Expected Surprise Prediction) filter helps investors identify stocks likely to beat earnings expectations by comparing the most recent analyst estimates against consensus estimates. Two examples highlighted are United Therapeutics (UTHR) with a +4.99% ESP and Eli Lilly (LLY) with a +1.21% ESP, both positioned to potentially surprise positively in their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now | The article explains how the Zacks Earnings ESP (Expected Surprise Prediction) filter helps investors identify stocks likely to beat earnings expectations by comparing the most recent analyst estimates against consensus estimates. Two examples highlighted are United Therapeutics (UTHR) with a +4.99% ESP and Eli Lilly (LLY) with a +1.21% ESP, both positioned to potentially surprise positively in their upcoming earnings reports. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm | A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | neutral | 0 | 1 |
| 3 Reasons to Avoid UTHR and 1 Stock to Buy Instead - Yahoo Finance | 3 Reasons to Avoid UTHR and 1 Stock to Buy Instead Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Why United Therapeutics (UTHR) Stock Is Up Today - Quiver Quantitative | Why United Therapeutics (UTHR) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 1, 2026 | neutral | 0 | 0.6 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback | A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback | A U.S. District Court ruled that two claims of United Therapeutics' '327 patent are valid and infringed by Liquidia's lead drug Yutrepia, causing a 57% decline in LQDA stock. Liquidia plans to remove the PH-ILD indication from Yutrepia's label to potentially preserve the drug's availability, narrowing its addressable market. The ruling creates significant uncertainty around Yutrepia's commercial outlook, with United Therapeutics seeking injunctive relief while Liquidia pursues appeals. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% | United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13% | United Therapeutics won a patent infringement ruling against Liquidia Technologies, with the court finding that Liquidia's Yutrepia infringes two claims of UTHR's patent covering inhaled treprostinil for PH-ILD treatment. Yutrepia may lose its PH-ILD label or face market removal, reducing competition for UTHR's Tyvaso products and potentially resulting in monetary damages for past infringement. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | neutral | 0 | 1 |
| United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last? | United Therapeutics shares surged 12.5% following a Delaware court ruling that Liquidia's Yutrepia infringes on UTHR's patent for inhaled treprostinil, potentially restricting competition for UTHR's Tyvaso products. However, the stock faces headwinds as consensus EPS estimates were revised 1.4% lower over the past 30 days, and the company is expected to report declining earnings and flat revenue growth. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bearish | -0.5 | 1 |
| Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today - The Globe and Mail | Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today The Globe and Mail | View source ↗ | The Globe and Mail | Sep 30, 2026 | neutral | 0 | 0.6 |
| United Just Pulled The Ultimate Bull Move, As Its Chief Rival Collapsed - Investor's Business Daily | United Just Pulled The Ultimate Bull Move, As Its Chief Rival Collapsed Investor's Business Daily | View source ↗ | Investor's Business Daily | Sep 30, 2026 | neutral | 0 | 0.6 |
| Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today - Yahoo Finance | Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today Yahoo Finance | View source ↗ | Yahoo Finance | Sep 30, 2026 | neutral | 0 | 0.6 |
| United Therapeutics (UTHR) Stock Looks Undervalued Following TETON PPF Enrollment News - Yahoo Finance | United Therapeutics (UTHR) Stock Looks Undervalued Following TETON PPF Enrollment News Yahoo Finance | View source ↗ | Yahoo Finance | Aug 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.